Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Sidney A. Spector"'
Autor:
Francis G. Ogrinc, Meredith Schultz, Sidney A. Spector, Hugh J. McMillan, Michelle A. Farrar, Elaine Kernbauer, Kathryn J. Swoboda, Sarah T. Kavanagh, Julie Parsons, Douglas M. Sproule, Kevin A. Strauss, Bryan E. McGill, James L’Italien, Douglas E. Feltner, Marcia Farrow, Uwe Ernst
Publikováno v:
Neuropediatrics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6257e8129226f920f24cc41cc31c25aa
https://doi.org/10.1055/s-0039-1698169
https://doi.org/10.1055/s-0039-1698169
Autor:
Francis G. Ogrinc, Michelle A. Farrar, Jennifer M. Kwon, James L’Italien, Kayoko Saito, Francesco Muntoni, Douglas M. Sproule, Imran Kausar, Susan T. Iannaccone, Claudia A. Chiriboga, Elaine Kernbauer, Meredith Schultz, Hugh J. McMillan, Kevin A. Strauss, Jena M. Krueger, Kathryn J. Swoboda, Bryan E. McGill, Mariacristina Scoto, Julie A. Parsons, Sarah Kavanagh, Marcia Farrow, Sidney A Spector, Douglas E. Feltner
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 90:e7.1-e7
BackgroundOnasemnogene abeparvovec (AVXS-101) is a gene-replacement therapy that treats the genetic root cause of SMA, biallelic survival motor neuron 1 gene (SMN1) deletion/mutation. In a phase 1 study, AVXS-101 improved survival and motor function
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0f4e3af2f4cb0a6a6bb303decd02b4f
https://doi.org/10.1136/jnnp-2019-abn-2.20
https://doi.org/10.1136/jnnp-2019-abn-2.20
Autor:
G. Tennekoon, Nancy L. Kuntz, Susan T. Iannaccone, S. Kavanagh, J. Mendell, Brian K. Kaspar, Elaine Kernbauer, Douglas E. Feltner, James L’Italien, Richard S. Finkel, Sidney A Spector, Thomas O. Crawford, J. Day, Francis G. Ogrinc, Russell J. Butterfield, J. Whittle, Perry B. Shieh, Anne M. Connolly, Basil T. Darras, Douglas M. Sproule
Publikováno v:
Neuromuscular Disorders. 29:S207
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d69c647d4fc1638b9f50133225a9288a
https://doi.org/10.1016/j.nmd.2019.06.594
https://doi.org/10.1016/j.nmd.2019.06.594
Autor:
S. Kavanagh, Bryan E. McGill, Kevin A. Strauss, Elaine Kernbauer, Douglas M. Sproule, Francis G. Ogrinc, Michelle A. Farrar, Julie A. Parsons, Sidney A Spector, Marcia Farrow, James L’Italien, Meredith Schultz, Hugh J. McMillan, Douglas E. Feltner, Kathryn J. Swoboda
Publikováno v:
Neuromuscular Disorders. 29:S183
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a79410a36389d6c764519c77e77fbe9
https://doi.org/10.1016/j.nmd.2019.06.512
https://doi.org/10.1016/j.nmd.2019.06.512
Autor:
Kathryn J. Swoboda, Marcia Farrow, Elaine Kernbauer, Kevin A. Strauss, Sidney A Spector, Meredith Schultz, Douglas E. Feltner, Francis G. Ogrinc, Hugh J. McMillan, Michelle A. Farrar, Julie Parsons, Douglas M. Sproule, Ian E. Alexander, Bryan E. McGill, James L’Italien
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 90:A5.3-A6
IntroductionSMA is a neurodegenerative disease caused by biallelic deletion/mutation of the survival motor neuron 1 gene (SMN1). Copies of a similar gene (SMN2) modify disease severity. In a phase 1 study, SMN GRT onasemnogene abeparvovec (AVXS-101)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75785da2889eef2d09a02b1eb7335987
https://doi.org/10.1136/jnnp-2019-anzan.14
https://doi.org/10.1136/jnnp-2019-anzan.14
Autor:
Ricardo F. Allegri, H. Michael Arrighi, Pablo M. Bagnati, Menghis Bairu, Sonia Brucki, Tal Burt, Lorne Cheeseman, Richard Chin, Debbie N. Cote, Jeffrey Cummings, Stephanie Danandjaja, P. Murali Doraiswamy, Murat Emre, James (Dachao) Fan, Yoko Fujimoto, Michel Grothe, Ibrahim Hakan Gürvit, Spencer Guthrie, Harald Hampel, Lynne Hughes, Michael Hüll, Hilal İlbars, Takeshi Iwatsubo, Roy W. Jones, Nadina C. Jose, Amir Kalali, Seong Yoon Kim, Miia Kivipelto, Bernd J. Krause, Jens Kurth, Huafang Li, Francesca Mangialasche, Hans J. Möbius, Ricardo Nitrini, Tiia Ngandu, Muriel O’Byrne, Peter Schüler, Klaudius Siegfried, Sidney A. Spector, Stefan Teipel, Yağiz Üresin, Michael Weiner, Jing Yin, Xue (Kate) Zhong
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ddf95cb08be205d45de9a3c12a30420
https://doi.org/10.1016/b978-0-12-411464-7.00027-4
https://doi.org/10.1016/b978-0-12-411464-7.00027-4
Autor:
Sidney A. Spector
Decades ago, pharmacogenetic research established that one’s genetic profile might predict efficacy and safety of medicines. Polymorphic expression of isoenzymes of the cytochrome P-450 enzyme system explains a significant amount of the variability
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75ee398a935d4728847d3fd8fe60d5d3
https://doi.org/10.1016/b978-0-12-411464-7.00021-3
https://doi.org/10.1016/b978-0-12-411464-7.00021-3
Autor:
Sidney A. Spector
The burgeoning field of pharmacogenomics holds the promise to uncover genetic risk factors for both rare and common diseases, identify genetically based inter-individual responses to medicines, and enrich clinical trials with more genetically homogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::155d13b16a82b74b10aedba51cc07005
https://doi.org/10.1016/b978-0-12-411464-7.00020-1
https://doi.org/10.1016/b978-0-12-411464-7.00020-1
A rapid increase in the globalization of clinical trials is being driven by a need for lower cost, greater speed, and higher quality. Increasing costs—approximately 20% per year—account for much of this effort. Trials in developing countries—do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b64bfd64df2abe1504d6e4d7eba1e9f0
https://doi.org/10.1016/b978-0-12-411464-7.00004-3
https://doi.org/10.1016/b978-0-12-411464-7.00004-3
Autor:
Marinos C. Dalakas, Irwin M. Feuerstein, Boyd M. Koffman, Ben F. Hurley, Jeffery T. Lemmer, Thomas A. Fleisher, Sidney A. Spector
Publikováno v:
Muscle & Nerve. 20:1242-1248
We studied the effects of a 12-week progressive resistance strength training program in weakened muscles of 5 patients with sporadic inclusion body myositis (IBM). Strength was evaluated with Medical Research Council (MRC) scale ratings and quantitat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9e20bc775fa5f3997a6d0d61dbb1532
https://doi.org/10.1002/(sici)1097-4598(199710)20:10<1242::aid-mus6>3.0.co
https://doi.org/10.1002/(sici)1097-4598(199710)20:10<1242::aid-mus6>3.0.co